Top Stories
Top Stories
Biotech and Pharma

AstraZeneca to sell antibiotics business to Pfizer

Pharmaceutical company AstraZeneca said it had agreed to sell its small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5 billion. 

    The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development, it said. 

    Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, AstraZeneca said, plus up to $250 million in milestones, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets. 

    The British company said the agreement did not impact its financial guidance for 2016. 

Viagra made by Pfizer and Nexium made by AstraZeneca.
Getty Images

Follow CNBC International on  and Facebook

Related Tags